Clinipace Acquisition Pan-Asia CRO, Choice Pharma
Choice Pharma provides Clinipace a significant Pan-Asia footprint
Clinipace Worldwide announced its merger with Choice Pharma. The merger expands Clinipace's global reach to include new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
The combined company now has 640 staff in 30 countries, and experience managing over 1500+ clinical trials, and over 300 regulatory and strategic development engagements
There are no layoffs or office closings planned; and the new combined organization will continue to hire throughout the year. Terms of the transaction will not be disclosed.
This is the 5th acquisition by Clinipace in recent years.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
